| Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters M Ketteler, GA Block, P Evenepoel, M Fukagawa, CA Herzog, L McCann, ... Kidney international 92 (1), 26-36, 2017 | 1005 | 2017 |
| Derangements of coagulation and fibrinolysis in critically III patients with sepsis and septic shock MG Vervloet, LG Thijs, CE Hack Seminars in thrombosis and hemostasis 24 (01), 33-44, 1998 | 438 | 1998 |
| Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease MH de Borst, MG Vervloet, PM ter Wee, G Navis Journal of the American Society of Nephrology 22 (9), 1603-1609, 2011 | 354 | 2011 |
| Diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder: Synopsis of the kidney disease: improving global outcomes 2017 clinical … M Ketteler, GA Block, P Evenepoel, M Fukagawa, CA Herzog, L McCann, ... Annals of internal medicine 168 (6), 422-430, 2018 | 345 | 2018 |
| Vascular calcification in chronic kidney disease: different bricks in the wall? M Vervloet, M Cozzolino Kidney international 91 (4), 808-817, 2017 | 280 | 2017 |
| Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use MC Weijmer, MG Vervloet, PM ter Wee Nephrology Dialysis Transplantation 19 (3), 670-677, 2004 | 267 | 2004 |
| Effects of dietary phosphate and calcium intake on fibroblast growth factor-23 MG Vervloet, FJ van Ittersum, RM Büttler, AC Heijboer, MA Blankenstein, ... Clinical Journal of the American Society of Nephrology 6 (2), 383-389, 2011 | 258 | 2011 |
| The role of phosphate in kidney disease MG Vervloet, S Sezer, ZA Massy, L Johansson, M Cozzolino, D Fouque, ... Nature Reviews Nephrology 13 (1), 27-38, 2017 | 218 | 2017 |
| Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized … L Schilder, SA Nurmohamed, FH Bosch, IM Purmer, SS den Boer, ... Critical care 18, 1-9, 2014 | 195 | 2014 |
| Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial DZI Cherney, CCJ Dekkers, SJ Barbour, D Cattran, AHA Gafor, ... The lancet Diabetes & endocrinology 8 (7), 582-593, 2020 | 194 | 2020 |
| Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders MG Vervloet, ZA Massy, VM Brandenburg, S Mazzaferro, M Cozzolino, ... The lancet Diabetes & endocrinology 2 (5), 427-436, 2014 | 177 | 2014 |
| High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study C Drechsler, P Evenepoel, MG Vervloet, C Wanner, M Ketteler, N Marx, ... Nephrology Dialysis Transplantation 30 (2), 288-293, 2015 | 163 | 2015 |
| Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide AJ Branten, PW du Buf-Vereijken, M Vervloet, JF Wetzels American Journal of Kidney Diseases 50 (2), 248-256, 2007 | 159 | 2007 |
| Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population A Covic, M Vervloet, ZA Massy, PU Torres, D Goldsmith, V Brandenburg, ... The lancet Diabetes & endocrinology 6 (4), 319-331, 2018 | 156 | 2018 |
| Renal and extrarenal effects of fibroblast growth factor 23 M Vervloet Nature Reviews Nephrology 15 (2), 109-120, 2019 | 150 | 2019 |
| Cinacalcet and achievement of the NKF/K-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice—the ECHO … P Urena, SH Jacobson, E Zitt, M Vervloet, F Malberti, N Ashman, ... Nephrology Dialysis Transplantation 24 (9), 2852-2859, 2009 | 144 | 2009 |
| Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2· 4 million patients from 11 countries: The CaReMe CKD study J Sundström, J Bodegard, A Bollmann, MG Vervloet, PB Mark, A Karasik, ... The Lancet Regional Health–Europe 20, 2022 | 142 | 2022 |
| Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation LC Baia, JK Humalda, MG Vervloet, G Navis, SJL Bakker, MH de Borst Clinical Journal of the American Society of Nephrology 8 (11), 1968-1978, 2013 | 141 | 2013 |
| Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? M Cozzolino, P Ureña-Torres, MG Vervloet, V Brandenburg, J Bover, ... Nephrology Dialysis Transplantation 29 (10), 1815-1820, 2014 | 136 | 2014 |
| European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D P Evenepoel, J Cunningham, S Ferrari, M Haarhaus, MK Javaid, ... Nephrology Dialysis Transplantation 36 (1), 42-59, 2021 | 124 | 2021 |
Martin De BorstUniversity Medical Center Groningenכתובת אימייל מאומתת בדומיין umcg.nl
